According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “
Several other research firms have also issued reports on CBPO. Credit Suisse Group AG upgraded China Biologic Products from a neutral rating to an outperform rating in a research note on Tuesday, July 5th. Jefferies Group increased their price objective on China Biologic Products from $136.00 to $155.00 and gave the stock a buy rating in a research note on Friday, August 5th.
Shares of China Biologic Products (NASDAQ:CBPO) opened at 120.18 on Tuesday. The stock has a market cap of $3.23 billion, a price-to-earnings ratio of 34.65 and a beta of 1.55. The stock’s 50 day moving average is $119.42 and its 200-day moving average is $117.26. China Biologic Products has a 1-year low of $95.70 and a 1-year high of $144.29.
China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported $1.26 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.10. The business earned $91.40 million during the quarter, compared to analyst estimates of $87.60 million. China Biologic Products had a return on equity of 19.65% and a net margin of 29.66%. China Biologic Products’s revenue was up 15.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.06 earnings per share. On average, analysts anticipate that China Biologic Products will post $4.33 EPS for the current year.
In related news, insider Zhijing Cbpo Liu sold 1,968 shares of the firm’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $124.32, for a total value of $244,661.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Wenfang Liu sold 2,900 shares of the firm’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $124.32, for a total value of $360,528.00. Following the completion of the transaction, the director now owns 3,383 shares in the company, valued at approximately $420,574.56. The disclosure for this sale can be found here. Insiders own 2.68% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Investment Management LLC purchased a new position in China Biologic Products during the second quarter valued at about $158,000. BNP Paribas Arbitrage SA boosted its position in China Biologic Products by 3,357.5% in the third quarter. BNP Paribas Arbitrage SA now owns 1,383 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 1,343 shares in the last quarter. Capstone Investment Advisors LLC purchased a new position in China Biologic Products during the second quarter valued at about $223,000. Legal & General Group Plc boosted its position in China Biologic Products by 23.5% in the second quarter. Legal & General Group Plc now owns 2,101 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 400 shares in the last quarter. Finally, Springbok Capital Management LLC purchased a new position in China Biologic Products during the first quarter valued at about $229,000. Institutional investors and hedge funds own 71.71% of the company’s stock.
China Biologic Products Company Profile
China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.